Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : How To Write Covered Calls - An Ongoing Real Case Study! -- Ignore unavailable to you. Want to Upgrade?

To: rkf who wrote (7196)	3/30/1998 5:26:00 PM
From: Herm	Respond to of 14162

Hi Kent, WOW! Nice VVUS price jump today on three times average volume. Now, that is typical of a REAL short squeeze! The hedge fund managers and all the daytrading sharks will be out for blood $$$$ this week. The shorts will pay back if they don't cover fast. Thirty percent (30%) of all VVUS outstanding shares are short right now! If this momentum is substained for a few more days VVUS can hit $15 by Friday easy. An FDA approval announcement, or 1st qtr. better earnings surprise, or new Asian country license fee $$ would do the trick. Not to mention a full VVUS blast of both barrels of a stock buy back program. I'm holding 5 June 15s Calls as my sideshow. I will exercise immediately if VVUS hits $15 before June. Then, I can milk 15 contracts at a time per CC event to get back my $$$ money fast.

To: rkf who wrote (7196)	3/31/1998 7:54:00 AM
From: Herm	Read Replies (1) \| Respond to of 14162

We may have another super VVUS up day! Just released on the wire: Tuesday March 31, 7:27 am Eastern Time Company Press Release VIVUS Expands Sales Force Primary Care Physicians As Main Target MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 31, 1998--VIVUS, Inc. (NASDAQ:VVUS - news) today announced an agreement to expand its sales organization from 74 to approximately 280 to increase the Company's coverage of the primary care physician (PCP) audience for its product MUSE(R) (alprostadil), a treatment for impotence. The Company expects that as of May 1998, these new representatives will have completed their training and will begin calling on targeted primary care physicians nationwide. ''The addition of these new sales representatives, along with our current territory managers, will allow VIVUS to increase our total physician coverage to 55,000 physicians,'' said Julian Gangolli, Vice President, Sales and Marketing of VIVUS. ''The expansion of the sales force is part of VIVUS' strategy to take advantage of the anticipated growth in demand. With the introduction by competitors of additional options for the treatment of impotence, we expect that more men will be brought into their PCP's office. Our presence in these doctors' offices will be important in ensuring that physicians and patients alike are educated about the benefits of MUSE.'' Innovex, a contract pharmaceutical organization and a division of Quintiles International, will provide VIVUS approximately 200 dedicated, full-time, primary care physician sales representatives. ''Innovex provides us with an immediate, experienced primary care physician sales force. These new representatives will be focusing solely on MUSE,'' stated Gangolli. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as MUSE. This therapy consists of a proprietary, non-invasive drug delivery system that delivers alprostadil via the urethra. Since the introduction of the product, MUSE has established itself as the most frequently prescribed treatment for impotence by specialists. To date, over 500,000 men have used MUSE. Note to Editors: MUSE is a registered trademark of VIVUS, Inc. Additional written materials, recent releases and company information are available through a variety of sources, including: the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). -------------------------------------------------------------------------------- Contact: VIVUS, Inc. Nina W. Ferrari, 650/934-5200 (Corporate Communications) David Yntema, 650/934-5200 (CFO) -------------------------------------------------------------------------------- More Quotes and News: Vivus Inc (Nasdaq:VVUS - news) Related News Categories: biotech, medical/pharmaceutical

To: rkf who wrote (7196)	3/31/1998 8:18:00 AM
From: Herm	Read Replies (2) \| Respond to of 14162

Hello Everyone! Doug's 2-Line Chart shows a SOLID up buy for VVUS. webbindustries.com Depending on your trading strategy, new money could do a quick buy/write for some quick CC premies. Check out some possible CC premies and the rate of return for one and two months out! webbindustries.com VVUS broke through the 50-day moving average between Friday and Monday on higher volume days. "Volume precedes price!" VVUS has provided an important momentum and daytrading signal. Expect that new money to jump into VVUS for wide price swings and some quick profits. The more volume and money, the higher possibility of a VVUS SHORT SQUEEZE! 30% of VVUS is held in short interest. That is some serious money and price increase for VVUS. This could be the big reversal to push VVUS past that $15.00 overhead resistance point. Once past $15 expect an EASY $20 within a week. 100% return in two weeks is not bad! Profit taking should kick in and us CCers should be selling CCs at the money and wait for that pull back to pocket that easy change in our accounts. For now, sit back and smile! Earnings report is coming out and I suspect a surprise and perhaps an FDA announcement! Why else would the CEO announce an increase in VVUS sales force? Without an FDA ok, the new plant is useless! It stands to reason the FDA finally gave them the OK. Just my opinion of course. I feel better about VVUS now that there is some action. Feeling good? Pick up some PUTs (as a sideshow) before the pull back to sweeten the $ pot! 207.95.154.130 You will notice that VVUS typically surpasses it's upper Bollinger Bands during upward price spurts. Very nice sign for our old viper. 207.95.154.130